These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 93511)

  • 1. Effect of mithramycin on widespread painful bone metastases in cancer of the breast.
    Davies J; Trask C; Souhami RL
    Cancer Treat Rep; 1979; 63(11-12):1835-8. PubMed ID: 93511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of an antiosteolytic agent in treatment of patients with bone metastases from breast cancer.
    Dady PJ; Coombes RC; Smith IE; Parsons CA; Ford HT; Gazet JC; Henk JM; Nash AG; Powles TJ
    Eur J Cancer (1965); 1980; Suppl 1():131-5. PubMed ID: 6459234
    [No Abstract]   [Full Text] [Related]  

  • 3. Mithramycin therapy in Paget's disease.
    Russell AS; Lentle BC
    Can Med Assoc J; 1974 Feb; 110(4):397-400. PubMed ID: 4273095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [186Re]HEDP in the palliation of painful bone metastases from cancers other than prostate and breast.
    Minutoli F; Herberg A; Spadaro P; Restifo Pecorella G; Baldari S; Aricò D; Altavilla G; Baldari S
    Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):355-62. PubMed ID: 17043634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial.
    Sciuto R; Festa A; Rea S; Pasqualoni R; Bergomi S; Petrilli G; Maini CL
    J Nucl Med; 2002 Jan; 43(1):79-86. PubMed ID: 11801708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Non-hormonal drug treatment in Paget's disease].
    Ryckewaert A; Lemaire V; Tubiana M
    Rev Rhum Mal Osteoartic; 1975 Nov; 42(11):693-8. PubMed ID: 131365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mithramycin in Paget's disease.
    Epstein S
    S Afr Med J; 1974 Jun; 48(31):1328-30. PubMed ID: 4276946
    [No Abstract]   [Full Text] [Related]  

  • 8. The effect of combined intravenous and oral clodronate treatment on bone pain in patients with metastatic prostate cancer.
    Kylmälä T; Tammela TL; Lindholm TS; Seppänen J
    Ann Chir Gynaecol; 1994; 83(4):316-9. PubMed ID: 7537482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Procollagen type I carboxy-terminal propeptide as a marker of osteoblastic bone metastases.
    Francini G; Gonnelli S; Petrioli R; Bruni S; Marsili S; Aquino A; Camporeale A
    Cancer Epidemiol Biomarkers Prev; 1993; 2(2):125-9. PubMed ID: 8467247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiopharmaceutical therapy for palliation of bone pain from osseous metastases.
    Pandit-Taskar N; Batraki M; Divgi CR
    J Nucl Med; 2004 Aug; 45(8):1358-65. PubMed ID: 15299062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 1 study of rhenium-186-HEDP in patients with bone metastases originating from breast cancer.
    de Klerk JM; van het Schip AD; Zonnenberg BA; van Dijk A; Quirijnen JM; Blijham GH; van Rijk PP
    J Nucl Med; 1996 Feb; 37(2):244-9. PubMed ID: 8667053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tin-117m(4+)-DTPA for palliation of pain from osseous metastases: a pilot study.
    Atkins HL; Mausner LF; Srivastava SC; Meinken GE; Cabahug CJ; D'Alessandro T
    J Nucl Med; 1995 May; 36(5):725-9. PubMed ID: 7537804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Newer agents in treating Paget's disease of bone.
    Goldfield EB
    Geriatrics; 1974 Dec; 29(12):61-9. PubMed ID: 4279196
    [No Abstract]   [Full Text] [Related]  

  • 14. Biochemical picture of bone metabolism in breast cancer patients with bone metastases.
    Berruti A; Torta M; Piovesan A; Raucci CA; Orlandi F; Panero A; Dogliotti L; Angeli A
    Anticancer Res; 1995; 15(6B):2871-5. PubMed ID: 8669881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of a new aminodiphosphonate (aminohydroxybutylidene diphosphonate) in patients with osteolytic lesions from metastases and myelomatosis. Comparison with dichloromethylene diphosphonate.
    Attardo-Parrinello G; Merlini G; Pavesi F; Crema F; Fiorentini ML; Ascari E
    Arch Intern Med; 1987 Sep; 147(9):1629-33. PubMed ID: 2957971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relative efficacy of 32P and 89Sr in palliation in skeletal metastases.
    Nair N
    J Nucl Med; 1999 Feb; 40(2):256-61. PubMed ID: 10025832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mithramycin in the treatment of Paget's disease of bone.
    Elias EG; Evans JT
    J Bone Joint Surg Am; 1972 Dec; 54(8):1730-6. PubMed ID: 4265871
    [No Abstract]   [Full Text] [Related]  

  • 18. [Palliation in patients with metastatic breast cancer often better with antitumour treatment than with only symptomatic treatment].
    Soetekouw PM; van Dongen R; Maas R; Bult P; Boetes C; Tjan-Heijnen VC
    Ned Tijdschr Geneeskd; 2007 Mar; 151(12):673-8. PubMed ID: 17447590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Variable behavior of urinary hydroxyproline in breast cancer with osseous metastases].
    Polico C; Nascimben O; Maccari F; Fazzin G
    Quad Sclavo Diagn; 1978 Dec; 14(4):486-93. PubMed ID: 757622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outpatient treatment of Paget's disease of bone with mithramycin.
    Lebbin D; Ryan WG; Schwartz TB
    Ann Intern Med; 1974 Nov; 81(5):635-7. PubMed ID: 4278469
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.